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Signposts on the Highway to Disease*Sudha Seshadri, MDC ardiovascular events are the leading causeof mortality and morbidity worldwide, soit is not surprising that over the past 3
decades there have been many attempts to identify
groups of persons at higher risk than others and to
reﬁne individual risk prediction. The Framingham
Heart Study risk scores for predicting coronary
artery disease and stroke have been widely used,
are recommended by the American Heart Associa-
tion, and have been integrated into a global cardio-
vascular disease (CVD) risk score (1–3). Most
recently, they formed the basis for the American
Heart Association/American College of Cardiology
guidelines for CVD risk assessment (4). These risk
scores use levels of risk factors at the time of risk
prediction (current exposure) to predict risk; how-
ever, the duration and severity of exposure to a
risk factor before the time of risk prediction
(remote exposure) also determines risk, as has
been demonstrated for the association of hyperten-
sion with stroke risk (5). Measures of subclinical
disease are useful markers of past exposure to
risk and pre-existing injury, signposts as it were
of how far along an individual might be on the
highway to disease. Incorporating such measures
into purely risk factor–based prediction algorithms
might, therefore, be expected to improve risk
prediction.
Coronary artery disease has been associated with
an increased risk of stroke. Mechanisms likely
include an increased risk of cerebral emboli from a
mural thrombus secondary to infarction or a low
ejection fraction and an increased susceptibility to
atrial ﬁbrillation (AF). However, coronary artery*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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the NIA (R01 AG08122, AG033193, U0149505).disease is also a marker of systemic atherosclerosis,
which is why the presence of documented coronary
artery disease (angina or myocardial infarction) is
an important component of the Framingham
Stroke Risk Proﬁle (FSRP) (1). As early as 1971,
William B. Kannel, a founder of the Framingham
Study, made the observation that although the
presence of a carotid bruit was associated with a
doubling of the risk of stroke, more often than not,
the brain infarction occurred in a vascular territory
different from that supplied by the carotid artery
with an audible bruit (6). This observation sug-
gested that the carotid bruit was an indicator of
an increased risk of stroke but largely as a marker
of severity of systemic vascular disease and not
necessarily as a direct effect of the local stenosis.
The same logic explains why incorporating a marker
of peripheral artery disease in the CHADS-VASc
(Congestive Heart Failure, Hypertension, Age, Dia-
betes, Sex and Vascular Disease) score improves
prediction of stroke risk in persons with AF. Thus,
although genetic, anatomic, environmental, and
other unknown factors do result in some hetero-
geneity in interindividual patterns of progression of
atherosclerosis in cerebral, coronary, and peripheral
artery beds, overall measures of atherosclerosis in
any 1 vascular bed reﬂect the extent of atheroscle-
rosis in other regions in the same person.
Measures of coronary artery calcium (CAC) load,
assessed using electron-beam computed tomography
or multidetector computed tomography are known to
be strongly correlated with the presence of coronary
atherosclerosis; hence, they are a robust marker of
subclinical coronary heart disease and systemic
atherosclerosis. Such imaging modalities also have
the advantages of being noninvasive, objective,
quantiﬁable, and repeatable. The possible advan-
tages, or lack thereof, of adding CAC to clinical risk
prediction scores in designing primary prevention
strategies for coronary artery disease have been
explored in some detail and were debated in a recent
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1117issue of Circulation Cardiovascular Imaging (7). How-
ever, the value of CAC as a stroke risk predictor has
been previously addressed in only 1 study of a
German cohort (8).SEE PAGE 1108In this issue of iJACC, nearly 6,800 persons of
diverse race/ethnic backgrounds, 45 to 84 years of
age, from the MESA (Multi-Ethnic Study of Athero-
sclerosis) who had baseline assessment of vascular
risk factor levels and of CAC were followed for
nearly a decade for the development of new-onset
strokes or transient ischemic attacks (9). CAC
scores, assessed as a continuous measure or as a
score above or below the American College of Car-
diology/American Heart Association recommended
cutoff of an Agatston score >300, were predictive of
incident stroke risk even after adjustment for age,
sex, race/ethnicity, body mass index, systolic and
diastolic blood pressure, blood pressure medication
use, total and high-density lipoprotein cholesterol,
statin use, cigarette smoking, and interim AF. There
was a 70% higher risk of stroke/transient ischemic
attack and 60% higher risk of stroke in persons with
a positive CAC status. CAC was an independent
predictor of stroke risk and improved discrimination
when added to the full model described earlier (C
statistic: 0.744 vs. 0.755) or when added to the
FSRP (C statistic: 0.664 vs. 0.706; p < 0.01). The
improvement in risk prediction was greatest for
persons at intermediate a priori risk of stroke.
Measures of reclassiﬁcation and number needed to
screen were not reported. Also not discussed was
whether the absence of CAC can be used to down-
grade stroke risk and defer preventive interventions
such as aspirin or anticoagulant agents.
A strength of this paper is its afﬁrmation of the
value of CAC as a marker of stroke risk in a
geographically and ethnically diverse sample. In
MESA, there were 38% white participants, 28%
black, 22% Hispanic, and 12% Chinese who lived in
different parts of the East and West Coast of the
United States; however, MESA does not include
other ethnic groups such as Native Americans and
South Asians who are groups at high risk of stroke.
Also, the study design of MESA excluded persons
with prevalent CVD; hence, this sample had a lower
stroke risk than average. A further caveat is that
the full model described here did not adjust for
previous coronary heart disease or heart failure,
and the FSRP does not take into account lipid
levels or measures of obesity. Neither of the 2
models presented accounted for peripheral vasculardisease or physical activity, and including those
simple clinical measures might have reduced the
incremental predictive utility of CAC.
What are the clinical implications of this study?
Should CAC scores be incorporated in stroke risk
prediction models? CAC is only 1 of many markers
of long-standing exposure to stroke risk factors such
as hypertension and of the severity of systemic
atherosclerosis. Other measures that do not involve
exposure to radiation include retinal examination,
urinary (micro) albumin levels, left ventricular mass
on echocardiography, tonometric assessment of
arterial stiffness, carotid intima-medial thickness,
and white matter hyperintensity volume on brain
magnetic resonance imaging, each of which has
been shown to be independently associated with
stroke risk and several of which have been shown
to improve risk prediction over models that only
consider baseline levels of risk factors. To date,
there has been no direct comparison of these
various markers of subclinical disease in the pre-
diction of stroke and total CVD risk. Further, the
incremental predictive value of subclinical measures
added to risk prediction algorithms that also include
multiple circulating biomarkers (such as B-type
natriuretic peptide,) remains unclear (10). Finally,
CAC is an imperfect measure of even coronary
artery disease because it cannot assess “vulnerable”
plaque characteristics. One study found that
noninvasive assessment of carotid plaque charac-
teristics improved the estimation of coronary risk
(11)! Needless to say, CAC scores are not a substitute
for clinical risk prediction scores; they re-
main promising but unproven adjuncts to clinical
prediction algorithms. The authors suggest that
clinical trials evaluating the effect of statins on
reducing stroke (as well as myocardial infarction)
risk in individuals without clinical cardiac disease
but positive CAC are needed, and indeed such
studies would clarify whether CAC will prove useful
in risk stratiﬁcation for primary prevention of
stroke.
This study does strengthen the overall message
that vascular neurologists and internists both need to
think of atherosclerosis as the underlying disease
with diverse clinical manifestations—manifestations
other than the presenting one are ignored at peril to
the physician and patient.
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